Meet the team
Peter Hudson, FTSE, BSc Hons, PhD
Director, Victorian Cancer Biologics
CSO, Avipep Pty Ltd.
Founder & Director,
Diantron Biomed Pty Ltd.
Dr. Peter Hudson is Director of the VCB (Victorian Cancer Biologics) consortium for the development of antibodies as clinical products, Chief Scientific Officer of AviPep Pty Ltd. and Co-chair of HUPO-HAI (Human Proteomics Antibody Initiative).
In 2014, Dr. Hudson led the VCB consortium to complete the first Phase 1 clinical trial of a novel cancer-targeting diabody. Peter has a distinguished career in antibody development, having developed both generic antibody designs and novel display and selection technologies. He co-founded Evogenix Pty Ltd. (2001) and Avipep Pty Ltd. (2005) to translate his products into the clinic. He was elected to the Australian ATSE Academy in 2002 and was awarded the AMRAD Biotechnology and CSIRO Chairman’s medals in 1997.
Dr. Hudson was also appointed the inaugural Adjunct Professor (Department of Biochemistry, La Trobe University) and has co-authored over 120 publications, including reviews in Nature Medicine and Nature Biotechnology. Dr. Hudson was formerly a chief research scientist, program and theme leader in CSIRO (1990-2008) and Deputy CEO and Scientific Director of the Cooperative Research Centre for Diagnostics (1995-2007). He was also Chair of Commercialisation for the AIBL Alzheimer’s Disease cluster and the CRC for Mental Health (2009-2012).
Dr. Hudson also provides expert scientific and commercialization advice in biotechnology, focused on protein-based biopharmaceuticals and clinical diagnostics through his consultancy company, Diantron Biomed Pty Ltd.